Researchers are reporting major progress in targeting KRAS, a cancer-driving protein long considered “undruggable.” Mutations in KRAS keep cells stuck in a constant growth mode, contributing to some of the most aggressive cancers, including pancreatic cancer.
Instead of simply trying to block KRAS activity, scientists are now developing “degrader” drugs that label the mutant protein as waste, allowing the cell to destroy it completely. This approach may help overcome the resistance that often limits traditional inhibitors.
Early results from the first clinical trial of a KRAS degrader are encouraging. At the same time, several trials are testing broader “pan-KRAS” inhibitors designed to target multiple KRAS mutations in one treatment.
Researchers emphasize that these therapies will likely work best in combination with other treatments to prevent cancer from adapting. After years of limited progress, this new strategy is bringing renewed optimism to the field.